Skip to main content

Table 2 Laboratory test results of pulmonary tuberculosis patients notified in Shanghai, China, in the first half of each of 2017 and 2018

From: Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China

CharacteristicsTotal
n (%)
(n = 6047)
PTB patients of 2017
n (%)
(n = 2938)
PTB patients of 2018
n (%)
(n = 3109)
p-value
Sputum smear   < 0.001
 Negative3784 (62.6)1812 (61.7)1972 (63.4) 
 Positive1802 (29.8)850 (28.9)952 (30.6) 
 Not available461 (7.6)276 (9.4)185 (6.0) 
Sputum culture   < 0.001
 Negative2123 (35.1)1000 (34.0)1123 (36.1) 
 Positive2786 (46.1)1285 (43.7)1501 (48.3) 
 Not available1138 (18.8)653 (22.3)485 (15.6) 
Xpert result for MTB   
 Negative782 (12.9)782 (25.2) 
 Positive909 (15.0)909 (29.2) 
 Not available4356 (72.0)2938 (100)1418 (45.6) 
Xpert result for RIF resistancea   
 Susceptible840 (92.4)840 (92.4) 
 Resistant69 (7.6)69 (7.6) 
Culture-based DST result for RIF resistanceb   0.784
 Susceptible2188 (78.5)1008 (78.4)1180 (78.6) 
 Resistant118 (4.2)58 (4.5)60 (4.0) 
 Not available480 (17.2)219 (17.0)261 (17.4) 
  1. PTB Pulmonary tuberculosis
  2. Xpert Xpert MTB/RIF
  3. MTB Mycobacteria of tuberculosis
  4. RIF Rifampicin
  5. DST Drug susceptibility test
  6. acalculated among Xpert MTB positive patients
  7. bcalculated among culture positive patients